This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2017 Apr;92(4):329-330.

doi: 10.1002/ajh.24667. Epub 2017 Feb 21.

FLT3 as a marker of minimal residual disease: Time to re-think?

Mark Levis¹

Affiliations

PMID: 28142203
DOI: 10.1002/ajh.24667

Free article

Comment

FLT3 as a marker of minimal residual disease: Time to re-think?

Mark Levis. Am J Hematol. 2017 Apr.

Free article

. 2017 Apr;92(4):329-330.

doi: 10.1002/ajh.24667. Epub 2017 Feb 21.

Author

Mark Levis¹

Affiliation

¹ Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, 21287, USA.

PMID: 28142203
DOI: 10.1002/ajh.24667

No abstract available

PubMed Disclaimer

Comment on

Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation.
Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO. Gaballa S, et al. Am J Hematol. 2017 Apr;92(4):331-337. doi: 10.1002/ajh.24632. Epub 2017 Feb 13. Am J Hematol. 2017. PMID: 28052408 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal